 SOUTH SAN FRANCISCO, Calif., July 23, 2021 GLOBE NEWSWIRE -- Cytokinetics, Incorporated Nasdaq: CYTK today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a price to the public of 27.50 per share. This includes the exercise in full by the underwriters of their option to purchase 1,500,000 additional shares of common stock. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, were approximately 316.25 million. 